Report
Jacob Mekhael ...
  • Thomas Vranken

Inventiva FIRST LOOK: $ 10m milestone from CTTQ

Inventiva has received a $ 10m milestone payment from Chia Tai-Tianqing Pharma (CTTQ), under their 2022 licensing deal to develop and commercialize lanifibranor for MASH in Greater China. This payment follows the successful settlement of Inventiva's second financing tranche and aligns with expectations shared in their 1Q25 update. Together with the €68m cash position at 1Q25 and € ~109m net proceeds from the second tranche, Inventiva is expected to be funded through 3Q26. The Phase 3 NATiV3 trial is fully recruited, with topline results expected in 2H26. With the funding overhang lifted, we maintain our € 7 TP and Buy rating.
Underlying
Inventiva SA

Inventiva is a clinical stage biotechnology research company delivering therapies in the areas of oncology, fibrosis and rare diseases. The most advanced clinical programs (IVA337 for systemic sclerosis in Non-Alcoholic Steato-Hepatitis and IVA336 for Maroteaux-Lamy syndrome-MPS VI) have demonstrated efficacy in relevant in vivo and in vitro models as well as safety in phase I and phase II clinical trials. Using its in-house drug discovery platform, which covers target validation, screening, chemistry, ADME and pharmacology, Co. is developing an internal oncology and fibrosis discovery pipeline with approaches centered on transcription factors, epigenetics targets and nuclear receptors.

Provider
KBC Securities
KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

 

Analysts
Jacob Mekhael

Thomas Vranken

Other Reports on these Companies
Other Reports from KBC Securities

ResearchPool Subscriptions

Get the most out of your insights

Get in touch